COG.L

Cambridge Cognition Holdings Plc
Cambridge Cognition - Directorate Change
18th October 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 6785I
Cambridge Cognition Holdings PLC
18 October 2024
 

Homepage - Cambridge Cognition

 

18 October 2024

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Directorate change

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that, further to the announcement made on 12 September 2024 in which it stated that Dr Matthew Stork had stepped down as Chief Executive Officer, the Company has now received the formal resignation of Dr Stork as a Director of the Company and all subsidiary entities of which he was a Director. 

 

 

Enquiries:

 

Cambridge Cognition Holdings plc 

Dr Steven Powell, Chairman

c/o Hudson Sandler 

Panmure Liberum Limited (NOMAD and Joint Broker) 

Freddy Crossley / Will Goode / Mark Rogers 

Rupert Dearden 

Tel: 020 7886 2968 

(Corporate Finance) 

(Corporate Broking) 

 

Dowgate Capital Limited (Joint Broker) 

David Poutney / James Serjeant 

 

Tel: 020 3903 7715 

 

 

Hudson Sandler (Financial PR and IR) 

Dan de Belder / Hattie Dreyfus / Harry Griffiths

 

Tel: 020 7796 4133 

cog@hudsonsandler.com

 


Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit: https://cambridgecognition.com/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAGZMMGRNMGDZM]]>
TwitterFacebookLinkedIn